These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29682277)

  • 1. The Allergic Rhinitis Clinical Investigator Collaborative (AR-CIC): verification of nasal allergen challenge procedures in a study utilizing an investigational immunotherapy for cat allergy.
    Neighbour H; Soliman M; Steacy LM; Hickey P; Forbes B; Larché M; Ellis AK
    Clin Transl Allergy; 2018; 8():15. PubMed ID: 29682277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Allergic Rhinitis - Clinical Investigator Collaborative (AR-CIC): nasal allergen challenge protocol optimization for studying AR pathophysiology and evaluating novel therapies.
    Ellis AK; Soliman M; Steacy L; Boulay MÈ; Boulet LP; Keith PK; Vliagoftis H; Waserman S; Neighbour H
    Allergy Asthma Clin Immunol; 2015; 11(1):16. PubMed ID: 25945101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical symptoms and biomarkers of Bermuda grass-induced allergic rhinitis using the nasal allergen challenge model.
    Rawls M; Thiele J; Adams DE; Steacy LM; Ellis AK
    Ann Allergy Asthma Immunol; 2020 Jun; 124(6):608-615.e2. PubMed ID: 32173484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Repeatability of nasal allergen challenge results: Further validation of the allergic rhinitis clinical investigator collaborative protocols.
    Soliman M; Steacy LM; Thiele J; Adams DE; Neighbour HL; Ellis AK
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):607-613. PubMed ID: 29432965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the reproducibility of responses to nasal allergen challenge and effects of inhaled nasal corticosteroids.
    Bauer RN; Xie Y; Beaudin S; Wiltshire L; Wattie J; Muñoz C; Alsaji N; Oliveria JP; Ju X; MacLean J; Sommer DD; Keith PK; Satia I; Cusack RP; O'Byrne PM; Sperinde G; Hokom M; Li O; Banerjee P; Chen C; Staton T; Sehmi R; Gauvreau GM
    Clin Exp Allergy; 2023 Nov; 53(11):1187-1197. PubMed ID: 37794659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of silver birch and house dust mite extracts derived from licensed sublingual tablets for nasal allergen challenge.
    Olivieri B; Gil AJ; Stoenchev K; Durham SR; Scadding G
    Clin Transl Allergy; 2024 May; 14(5):e12360. PubMed ID: 38779783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical validation of controlled exposure to birch pollen in the Environmental Exposure Unit (EEU).
    Ellis AK; Soliman M; Steacy LM; Adams DE; Hobsbawn B; Walker TJ
    Allergy Asthma Clin Immunol; 2016; 12():53. PubMed ID: 27777594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The holo beta-lactoglobulin lozenge reduces symptoms in cat allergy-Evaluation in an allergen exposure chamber and by titrated nasal allergen challenge.
    Bergmann KC; Raab J; Graessel A; Zwingers T; Becker S; Kugler S; Zuberbier T; Roth-Walter F; Kramer MF; Jensen-Jarolim E
    Clin Transl Allergy; 2023 Jul; 13(7):e12274. PubMed ID: 37488734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen.
    Larson D; Patel P; Salapatek AM; Couroux P; Whitehouse D; Pina A; Johnson JL; Sever ML; Sanda S; Poyser J; Allio T; Scadding GW; Qin T; Shamji MH; Kwok WW; James EA; French D; Lelic A; Larché M; Altman MC; Togias A; Durham SR
    J Allergy Clin Immunol; 2020 Jun; 145(6):1585-1597. PubMed ID: 32169380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge.
    Scadding GW; Eifan AO; Lao-Araya M; Penagos M; Poon SY; Steveling E; Yan R; Switzer A; Phippard D; Togias A; Shamji MH; Durham SR
    Allergy; 2015 Jun; 70(6):689-96. PubMed ID: 25773990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 2 Years of Treatment With Sublingual Grass Pollen Immunotherapy on Nasal Response to Allergen Challenge at 3 Years Among Patients With Moderate to Severe Seasonal Allergic Rhinitis: The GRASS Randomized Clinical Trial.
    Scadding GW; Calderon MA; Shamji MH; Eifan AO; Penagos M; Dumitru F; Sever ML; Bahnson HT; Lawson K; Harris KM; Plough AG; Panza JL; Qin T; Lim N; Tchao NK; Togias A; Durham SR;
    JAMA; 2017 Feb; 317(6):615-625. PubMed ID: 28196255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.
    Corren J; Larson D; Altman MC; Segnitz RM; Avila PC; Greenberger PA; Baroody F; Moss MH; Nelson H; Burbank AJ; Hernandez ML; Peden D; Saini S; Tilles S; Hussain I; Whitehouse D; Qin T; Villarreal M; Sever M; Wheatley LM; Nepom GT; Sanda S;
    J Allergy Clin Immunol; 2023 Jan; 151(1):192-201. PubMed ID: 36223848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protocol for a randomised, double-blind, placebo-controlled study of grass allergen immunotherapy tablet for seasonal allergic rhinitis: time course of nasal, cutaneous and immunological outcomes.
    Steveling EH; Lao-Araya M; Koulias C; Scadding G; Eifan A; James LK; Dumitru A; Penagos M; Calderón M; Andersen PS; Shamji M; Durham SR
    Clin Transl Allergy; 2015; 5():43. PubMed ID: 26682038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Birch-induced allergic rhinitis: Results of exposure during nasal allergen challenge, environmental chamber, and pollen season.
    Gherasim A; Dietsch F; Beck M; Domis N; de Blay F
    World Allergy Organ J; 2023 Jul; 16(7):100801. PubMed ID: 37520615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allergen immunotherapy effectiveness in specific nasal reactivity of children with local allergic rhinitis.
    Loureiro G; Tavares B; Farinha I; Cunha F; Todo-Bom A
    Eur Ann Allergy Clin Immunol; 2024 Sep; ():. PubMed ID: 39219549
    [No Abstract]   [Full Text] [Related]  

  • 17. Technical and clinical validation of the Allergen BioCube
    Angjeli E; Gomes P; Lane KJ; Stein L; Abelson MB
    Immun Inflamm Dis; 2017 Mar; 5(1):78-84. PubMed ID: 28250927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation of controlled exposure to house dust mite in the environmental exposure unit (EEU).
    Hossenbaccus L; Linton S; Thiele J; Steacy L; Walker T; Malone C; Ellis AK
    Allergy Asthma Clin Immunol; 2021 Mar; 17(1):34. PubMed ID: 33771217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local and systemic effects of cat allergen nasal provocation.
    Scadding GW; Eifan A; Penagos M; Dumitru A; Switzer A; McMahon O; Phippard D; Togias A; Durham SR; Shamji MH
    Clin Exp Allergy; 2015 Mar; 45(3):613-23. PubMed ID: 25303516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fel d 1-derived synthetic peptide immuno-regulatory epitopes show a long-term treatment effect in cat allergic subjects.
    Couroux P; Patel D; Armstrong K; Larché M; Hafner RP
    Clin Exp Allergy; 2015 May; 45(5):974-981. PubMed ID: 25600085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.